Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer — Stella

Home/Metastatic Colorectal Cancer，NED/

View on ClinicalTrials.gov

Recruiting

Back to Metastatic Colorectal Cancer，NED trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Gastrointestinal Hospital, Sun Yat-sen University, Guangzhou, Guangdong

Key details

Phase

Safety & dosing

Sponsor

Yanhong Deng

Enrollment target

~52 participants

Started

August 2023

Primary completion

February 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 80 Years

Last updated December 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.